BY13 is a SRC-3 PROTAC degrader with a DC50 of 0.031 µM. BY13 selectively blocks the ER signaling pathway over that of androgen receptor (AR)) through down-regulating ERalpha level. BY13 potently overcomes endocrine resistance in breast cancer by inducing cell cycle arrest in G1 phase and apoptosis, with superior effect over Fulvestrant (HY-13636). BY13 significantly inhibits the growth of drug-resistant breast tumors without obvious toxicity in LCC2 xenograft mice model[1]. Pink: SRC-3 ligand (SI-2) (HY-101447), Blue: CRBN ligase ligand (HY-41547), Black: linker (HY-176226)
Molekulargewicht:
645.71
Formel:
C35H35N9O4
Target-Kategorie:
Apoptosis,Estrogen Receptor/ERR,PROTACs,Src
Anwendungsbeschreibung:
MCE Product type: Reference compound1
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
